Sugi Predict

Sugi Predict / Compounds / SCHEMBL3547706

SCHEMBL3547706

SCHEMBL3547706

COc1ccc(C(=O)O)cc1OC(F)(F)F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.71
▸ CA1 P00915 2/20 0.71
▸ CA2 P00918 2/20 0.71
▸ CA4 P22748 2/20 0.71
▸ CA6 P23280 2/20 0.71
▸ CA7 P43166 2/20 0.71
▸ CA9 Q16790 2/20 0.71
▸ CA14 Q9ULX7 2/20 0.71
▸ TPMT P51580 1/20 0.71
▸ HTT P42858 2/20 0.60
▸ LMNA P02545 2/20 0.60
▸ RAB9A P51151 2/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ TSHR P16473 4/20 0.57
▸ TTR P02766 2/20 0.54
▸ CYP1A2 P05177 2/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ CYP2C19 P33261 2/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ PKM P14618 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14248660 0.93 CA12 (0.71) CA12CA1CA2CA4CA6
SCHEMBL30708091 0.93 CA12 (0.71) CA12CA1CA2CA4CA6
SCHEMBL3367612 0.90 RXRA (0.54) CA12CA1CA2CA4CA6
SCHEMBL1105480 0.87 CYP1A2 (0.53) CA12CA1CA2CA4CA6
SCHEMBL15174514 0.85 CYP1A2 (0.51) CA12CA1CA2CA4CA6
SCHEMBL27051619 0.85 CA12 (0.50) CA12CA1CA2CA4CA6
SCHEMBL7361174 0.85 CA12 (0.73) CA12CA1CA2CA4CA6
SCHEMBL27051448 0.84 TSHR (0.73) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL29386353 0.84 CA12 (1.00) CA12CA1CA2CA4CA6
Veratric Acid SCHEMBL114848 0.84 CA12 (1.00) CA12CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528903-A Compounds for the treatment of spinal muscular atrophy PTC医疗公司 2025-02-28 — — CN disclosed
CN-108299314-B Compounds for the treatment of spinal muscular atrophy PTC医疗公司 2024-11-26 — — CN disclosed
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2024-02-29 — — US disclosed
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2024-02-29 — — US disclosed
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2024-02-29 — — US disclosed
US-11753407-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2023-09-12 — — US disclosed
US-11753407-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2023-09-12 — — US disclosed
US-11753407-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2023-09-12 — — US disclosed
US-20210276999-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2021-09-09 — — US disclosed
US-20210276999-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2021-09-09 — — US disclosed
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. 2015-01-01 — — US disclosed
EP-2812004-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-12-17 — — EP disclosed
WO-2013119916-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-08-15 — — WO disclosed
WO-2013119916-A2 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-08-15 — — WO disclosed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 — — US disclosed
WO-2009151626-A1 SUBSTITUTED (1, 2, 4-0XADIAZ0L-3-YL) INDOLIN-1-YL CARBOXYLIC ACID DERIVATIVES USEFUL AS S1P1 AGONISTS ARENA PHARMACEUTICALS, INC. (US) 2009-12-17 — — WO disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 — — US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 — — EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 — — EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067646-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CA12 4259/4885CA1 4572/4885CA2 4155/4885
US-20150005289-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CA12 4380/4885CA1 4656/4885CA2 4041/4885
US-20210276999-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, CPT1B, GYS1 CA12 4259/4885CA1 4572/4885CA2 4155/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE CA12 3880/4885CA1 4363/4885CA2 4383/4885
US-11753407-B2 Compounds for treating spinal muscular atrophy SMN1; SMN2, CPT1B, GYS1 CA12 4503/4885CA1 4753/4885CA2 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.